This project is funded by:
Age-associated neurodegenerative diseases, including dementias, such as Alzheimer’s disease (AD) and Frontotemporal dementia (FTD), and clinically overlapping conditions such as Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS), are increasing, in line with the aging worldwide population (1).
Some 982,000 individuals are living with dementia in the UK; 13,625 in Northern Ireland (2). The estimated economic impact in the UK is £42.5 billion, with projections of £90 billion by 2040 (3). ALS has a worldwide prevalence of 3.37 per 100,000 (4) and incidence and prevalence are increasing in Northern Ireland, in line with other European countries (5). Given the significant personal and societal burden of neurodegenerative conditions, research to improve understanding and identify novel therapeutic targets is urgently needed.
Neurodegenerative diseases share numerous overlapping mechanisms, including protein aggregation, lysosome and mitochondrial dysfunction and alterations in lipid metabolism (6-7). Cell-cell communication also plays a key role and improved understanding of early cellular events are vital to identify drug targets with utility at an earlier stage in the disease process (8). Disrupted pathways vary depending on the specific cell types involved, which in turn affects cell behaviour. Depending on their mutational status, some cell types may have a neuroprotective role, while others are neurotoxic (9). Changes in cell-to-cell communication is known to impact neuronal degeneration across a range of neurodegenerative conditions (10-13) however the mechanisms are poorly understood.
The project will investigate cell-to-cell communication between neuronal and non-neuronal cells in neurodegenerative conditions and investigate therapeutic strategies to modulate cell-cell communication.
The project aims to:
1. Characterise neuronal and non-neuronal cells in different neurodegenerative conditions.
2. Analyse cell-to-cell communication between neurons, glia, astrocytes and myocytes in response to disease-associated protein aggregates and patient serum.
3. Investigate the impact of novel and established therapeutic strategies on cell-cell interactions to reduce neuronal degeneration.
Important Information: Applications for more than one PhD studentship are welcome, however if you apply for more than one PhD project within Medicine, your first application on the system will be deemed your first-choice preference and further applications will be ordered based on the sequential time of submission. If you are successfully shortlisted, you will be interviewed only on your first-choice application and ranked accordingly. Those ranked highest will be offered a PhD studentship. In the situation where you are ranked highly and your first-choice project is already allocated to someone who was ranked higher than you, you may be offered your 2nd or 3rd choice project depending on the availability of this project.
Please note, the successful candidate will be required to obtain AccessNI clearance prior to registration due to the nature of the project.
Applicants should hold, or expect to obtain, a First or Upper Second Class Honours Degree in a subject relevant to the proposed area of study.
We may also consider applications from those who hold equivalent qualifications, for example, a Lower Second Class Honours Degree plus a Master’s Degree with Distinction.
In exceptional circumstances, the University may consider a portfolio of evidence from applicants who have appropriate professional experience which is equivalent to the learning outcomes of an Honours degree in lieu of academic qualifications.
If the University receives a large number of applicants for the project, the following desirable criteria may be applied to shortlist applicants for interview.
The University is an equal opportunities employer and welcomes applicants from all sections of the community, particularly from those with disabilities.
Appointment will be made on merit.
This project is funded by:
Our fully funded PhD scholarships will cover tuition fees and provide a maintenance allowance of £19,237 (tbc) per annum for three years* (subject to satisfactory academic performance). A Research Training Support Grant (RTSG) of £900 per annum is also available.
These scholarships, funded via the Department for the Economy (DfE) and the Vice Chancellor’s Research Scholarships (VCRS), are open to applicants worldwide, regardless of residency or domicile.
Applicants who already hold a doctoral degree or who have been registered on a programme of research leading to the award of a doctoral degree on a full-time basis for more than one year (or part-time equivalent) are NOT eligible to apply for an award.
*Part time PhD scholarships may be available, based on 0.5 of the full time rate, and will require a six year registration period (individual project advertisements will note where part time options apply).
Due consideration should be given to financing your studies.
1. Heemels, M.T. (2016). Neurodegenerative diseases. Nature,539(7628), pp179-180.
2. Alzheimer’s Research UK Dementia Statistics Hub (2024). Available from: https://dementiastatistics.org/statistics/the-economic-impact-of-dementia/
3. Alzheimer’s Research UK Dementia Statistics Hub (2024). Available from: https://dementiastatistics.org/statistics/the-economic-impact-of-dementia/
4. Park, J., Kim, J.E. and Song, T.J. (2022). The global burden of motor neuron disease: an analysis of the 2019 global burden of disease study. Frontiers in Neurology, 13, p.864339.
5. McCluskey, G., Duddy, W., Haffey, S., Morrison, K., Donaghy, C. and Duguez, S. (2022). Epidemiology and survival trends of motor neurone disease in Northern Ireland from 2015 to 2019. European journal of neurology, 29(3), pp.707-714.
6. Gan, L., Cookson, M.R., Petrucelli, L. and La Spada, A.R. (2018). Converging pathways in neurodegeneration, from genetics to mechanisms. Nature neuroscience, 21(10), pp.1300-1309.
7. Yadav, R.S. and Tiwari, N.K. (2014). Lipid integration in neurodegeneration: an overview of Alzheimer’s disease. Molecular neurobiology, 50(1), pp.168-176.
8. Balusu, S., Praschberger, R., Lauwers, E., De Strooper, B. and Verstreken, P. (2023). Neurodegeneration cell per cell. Neuron, 111(6), pp.767-786.
9. Stoklund Dittlau, K., Terrie, L., Baatsen, P., Kerstens, A., De Swert, L., Janky, R.S., Corthout, N., Masrori, P., Van Damme, P., Hyttel, P. and Meyer, M. (2023). FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms. Molecular Neurodegeneration, 18(1), p.5.
10. Zhang, Y., Wang, Z., Xu, F., Liu, Z., Zhao, Y., Yang, L.Z. and Fang, W. (2024). Progress of Astrocyte-Neuron Crosstalk in Central Nervous System Diseases. Neurochemical Research, pp.1-21.
11. Ma, W., Geng, Y., Liu, Y., Pan, H., Wang, Q., Zhang, Y. and Wang, L. (2024). The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson’s disease: a narrative review. Frontiers in Aging Neuroscience, 16, p.1345918.
12. Stoklund Dittlau, K. and Freude, K. (2024). Astrocytes: The Stars in Neurodegeneration?. Biomolecules, 14(3), p.289.
13. Stoklund Dittlau, K. and Van Den Bosch, L. (2023). Why should we care about astrocytes in a motor neuron disease? Frontiers in Molecular Medicine, 3, p.1047540.
Submission deadline
Monday 3 February 2025
04:00PM
Interview Date
w/c 10 March 2025
Preferred student start date
15 September 2025
Telephone
Contact by phone
Email
Contact by email